Back to Results

Via Pharmaceuticals (VIAP)

Via Pharmaceuticals, Inc. is a development-stage biotechnology company listed on OTC Markets under the symbol VIAP. The company focuses on discovering and developing small-molecule compounds for cardiovascular and metabolic diseases, with research aimed at conditions such as vascular inflammation, high cholesterol, high triglycerides, insulin sensitization, and diabetes. Its pipeline includes VIA-3196, a liver-directed thyroid hormone receptor beta agonist that is Phase 1 ready and intended to address dyslipidemia, including elevated LDL cholesterol, triglycerides, and Lp(a). The company is also developing a DGAT1 inhibitor in preclinical work for type 2 diabetes and related metabolic disorders, and VIA-2291, a 5-lipoxygenase inhibitor that has completed a third Phase 2 clinical trial for atherosclerotic plaque. Via Pharmaceuticals also has research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. The company was founded in 2004 and is headquartered in San Francisco, California.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Market Cap
OTC-VIAP
Not available
Not available
Not available
Fair
0.0%
0.02 K
Valuation • Fair Value

Via Pharmaceuticals (OTC-VIAP) Fair Value by Valuation Model

No usable valuation estimate is currently available for Via Pharmaceuticals (OTC-VIAP); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for Via Pharmaceuticals (OTC-VIAP). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for Via Pharmaceuticals (OTC-VIAP)

Review the profitability and growth indicators currently supported by the latest data.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Via Pharmaceuticals (OTC-VIAP) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Via Pharmaceuticals (OTC-VIAP)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Via Pharmaceuticals (OTC-VIAP). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Via Pharmaceuticals (OTC-VIAP)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Via Pharmaceuticals (OTC-VIAP). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Via Pharmaceuticals (OTC-VIAP) Stock Forecast & Technical Outlook

Review Via Pharmaceuticals (OTC-VIAP) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Via Pharmaceuticals (OTC-VIAP) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Via Pharmaceuticals (OTC-VIAP) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Via Pharmaceuticals (OTC-VIAP) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Via Pharmaceuticals (OTC-VIAP)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Via Pharmaceuticals (OTC-VIAP) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Via Pharmaceuticals (OTC-VIAP) Stock FAQ

Data-supported answers about Via Pharmaceuticals (OTC-VIAP), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
Not available
No reliable estimate from the currently supported inputs
Financial Health
Fair
Current financial-health read

A reliable fair value estimate is not currently available for Via Pharmaceuticals (OTC-VIAP). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The current financial health read for Via Pharmaceuticals (OTC-VIAP) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Via Pharmaceuticals (OTC-VIAP).

The current market capitalization listed for Via Pharmaceuticals is 0.02 K.

The ticker symbol for Via Pharmaceuticals is OTC-VIAP, and the stock is listed on OTC Markets.

Via Pharmaceuticals (OTC-VIAP) is listed on OTC Markets.

Similar Biotechnology Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B